Introduction
Despite its immunologically privileged property, the eye can develop inflammation and immunological disease. 1 Birdshot chorioretinopathy (BCR) is a rare chronic autoimmune uveitis with a characteristic focal lymphocytic infiltrate in the choroid-affecting function. 2 BCR is strongly associated with human leukocyte antigen (HLA)-A29, one of the 21 serologically defined variants of HLA-A gene. 2 The relative risk of developing BCR among HLA-A*29-positive individuals has been estimated to be 50-224. Although HLA-A*29 occurs commonly in all ethnic populations with a frequency of 4.5% in Caucasians, 3.5% in Africans and 1.7% in Asians, 3 BCR is almost exclusively found in Caucasians and is rare even in HLA-A*29-positive Caucasians, suggesting that host genetic factors besides HLA-A*29 play a role in BCR disease.
The recent discovery of killer cell immunoglobulin-like receptors (KIR) led a series of epidemiological studies implicating KIRs in antiviral immunity, 4-6 autoimmune diseases [7] [8] [9] [10] and cancer progression. 11, 12 KIRs are key receptors of human natural killer (NK) cells, a subset of lymphocytes that trigger early immune response against infection and tumors, while maintaining tolerance to healthy self. 13, 14 Further, CD8 þ cytotoxic T lymphocytes (CTL) with memory phenotype and CD4 þ CD28 null T cells also express KIRs indicating KIRs' regulatory role in antigen-specific adaptive immunity. 15, 16 Given the importance of KIR receptors in innate and adaptive immunity and their genomic associations with various diseases, we examined whether BCR could also be associated with some KIR genes in a Caucasian population. Although it was never studied whether KIRexpressing NK cells or T cells were crucial players in BCR pathogenesis, the aggregations of lymphocytes in the deep choroid and in the optic nerve head observed by a histopathological analysis of a BCR patient 17 indicates a possible role of these lymphocyte subsets.
Fourteen KIR receptors triggering either inhibition (3DL1-3, 2DL1-3, 2DL5) or activation (3DS1, 2DS1-5) or both (2DL4) have been identified. 18 Inhibitory KIR receptors (iKIR) recognize distinct motifs of the polymorphic HLA class I molecules and trigger signals that stop effector function of NK cells. KIR2DL2 and 2DL3 bind a subset of HLA-C allotypes containing an asparagine at amino-acid position 80 of the heavy chain (HLA-C1 alleles) and KIR2DL1 binds the remaining HLA-C allotypes with lysine 80 (HLA-C2 alleles). [19] [20] [21] KIR3DL1 binds 40% of the HLA-B allotypes containing a serologically defined Bw4 epitope 22, 23 and KIR3DL2 binds HLA-A3/A11. 24, 25 The strength of these interactions is highly sensitive to polymorphism of the KIR and HLA genes, as well as the HLA-bound peptide sequence. [26] [27] [28] [29] [30] [31] [32] KIR2DL4 binds trophoblast-specific HLA-G and regulates vascular growth in the decidua that facilitates successful pregnancy. 33, 34 Ligands for KIR2DL5, KIR3DL3 or any activating KIR (aKIR) have not been identified.
Based on genetic epidemiological studies, 4 in vitro activation 35, 36 and weak binding of aKIR-Fc proteins 37 and tetramers, 38 three aKIRs are thought to bind the same HLA class I ligands as their homologous inhibitory counterparts at low affinity. KIR3DS1 that shares 97% sequence similarity with KIR3DL1 in the extracellular immunoglobulin (Ig)-domains is believed to bind HLABw4 ligand. 4 Similarly, KIR2DS1 (homologue of 2DL1) and 2DS2 (homologue of 2DL2) are considered to bind weakly to HLA-C2 and HLA-C1, respectively. 37, 38 The functional analogues of aKIR receptors in mice, LY49D and LY49H were shown to bind directly to virus-encoded proteins expressed by cells infected with mouse cytomegalovirus and initiate the activation cascade leading to cytolysis of infected cells. 39, 40 A prediction from these studies was that human aKIR may also bind pathogenencoded, or pathogen-induced determinants expressed on the surface of infected or stressed cells and trigger NK lysis. KIR receptors are encoded by a family of tightly clustered genes on leukocyte receptor complex at chromosome 19q13.4. 41 The number and type of KIR genes vary substantially between haplotypes 41, 42 and display sequence polymorphism. 43, 44 Patterns of linkage disequilibrium divide the KIR haplotype between 3DP1 and 2DL4 into two halves. 44, 45 For genes within each half there is significant linkage disequilibrium, but it is much less for genes in the two different halves. Based on the gene content, the centromeric (C) and telomeric (T) halves can be subdivided into small motif groups such as C1, C2, C3, Cx, T1, T2 and Tx. Combinations of these C and T motif groups were suggested to generate exponential KIR haplotypic diversity. 46 The independent segregation of KIR haplotypes with different gene content yields diversity in the number and type of KIR genes inherited in individuals, which consequently produce a population diversity in KIR gene frequencies and genotype profiles. 46 Since KIR genes at chromosome 19q13. 4 and HLA genes at chromosome 6p21.3 are polymorphic and display significant variations, the independent segregation of these unlinked gene loci produce diversity in the number and type of KIR þ HLA gene combinations inherited in individuals. 47 To examine whether KIR-HLA combinations confer risk for developing BCR, we typed KIR and HLA class I genes in patients and controls carrying HLA-A*29 as well as controls lacking HLA-A*29 from a French Caucasian population. This provides an appropriate system to assess the sole effect of KIR genes in conferring risk of BCR since the impact of HLA-A*29, the allele known to confer risk for disease, its linked HLA-B and HLA-C loci 3 and their force on coevolving KIR genes 48 are likely identical in patients and controls carrying HLA-A*29.
Results
Differential distribution of KIR genes in patients and controls carrying HLA-A*29 To test the possibility that KIR genes are involved in risk of developing BCR, we first compared the KIR gene profiles among the HLA-A*29-positive BCR patients, HLA-A*29-positive controls (termed A*29
PC
) and HLA-A*29-negative controls (termed A*29
NC
). Based on the presence and absence of known KIR genes, 32 distinct KIR genotypes were identified from all individuals analyzed in the present study ( Figure 1 ). The patients displayed only 13 of 32 genotypes. The overall distribution of KIR genotypes between patients and either control group was significantly different (Po0.05). Particularly, the KIR genotypes with C2-T1 motifs carrying 2DS2, 2DL2, 2DL1, 3DL1 and 2DS4 genes were found more commonly in patients (57.3%) than HLA-A*29 PC (40%), P ¼ 0.017, odds ratios (OR) ¼ 2.0, 95% confidence interval (CI) ¼ 1.15-3.51 ( Figure 1 ).
All patients carried KIR3DL1 and KIR2DS4, while B7% of controls lacked them (Figure 1 ). Genotypes deleted for both KIR3DL1 and 2DS4 were reported to occur 5-7% in Caucasian populations including those studied from southeast 49 and western 50 France. The ubiquitous distribution of 3DL1 and 2DS4 was previously reported only in populations of African ancestry. 46 Subtyping analyses revealed that the majority of patients, but not controls, carried functional 3DL1 and 2DS4 variants (Figure 2 
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T1 T2 Figure 1 Genotypes containing KIR2DS2-2DL2-2DL1-3DL1-2DS4 are predominant in birdshot chorioretinopathy (BCR) patients. In our study group of 307 individuals, 32 distinct genotypes were observed, which differed each other by the presence (shaded box) and absence (white box) of 14 killer cell immunoglobulin-like receptors (KIR) genes. Frequency of each genotype is expressed as a percentage and defined as the number of individuals having the genotype divided by the number of individuals studied (n) in the given study group. Based on the KIR gene content, the centromeric (C) and telomeric (T) halves are subdivided into the following motif groups:
The difference in the distribution of C2-T1 motifs between patients (57.3%) and HLA-A*29 PC (40%) was statistically significant, P ¼ 0. (Table 2 ). There was a trend toward higher frequencies of homozygotes for C1/C1 and Bw4/Bw4 among BCR patients. In contrast, the reciprocal association displaying increased frequencies of C2/C2 and Bw6/Bw6 homozygotes was observed in HLA-A*29-negative controls. Over 75% of the patients and HLA-A*29 PC carried the subset of Bw4 allotypes containing threonine 80 (Bw4 T80 ), which provides weaker inhibition than Bw4 containing isoleucine at this position (Bw4   I80   ) 23,53 (Table 2 ). In contrast, most Bw4-positive individuals in the HLA-A*29
NC group carried the strongly inhibitory Bw4 epitope, and frequency of these combined epitopes from HLA-B and HLA-A allotypes (termed Bw4 I80 þ ) was higher in HLA-A*29 NC compared to A*29-positive subjects ( Table 2) .
iKIR þ HLA combinations implicated for weak inhibition were frequent in BCR patients Since KIRs on chromosome 19q13.4 and HLA on chromosome 6p21.3 are substantially polymorphic, their independent segregation produces diverse KIR þ HLA combinations among individuals. 47 To investigate whether KIR-HLA interactions confer risk for BCR, we assessed four well-defined iKIR þ HLA pairs in each subject. Patients displayed increased frequencies of 3DL1 þ Bw4 and 2DL2/3 þ C1, and decreased frequencies of 2DL1 þ C2 and 3DL2 þ A3/11, compared to controls (Table 2) . Since KIR2DL2 binds HLA-C1 with greater affinity than its allelic variant 2DL3, 27, 41 we assessed The function of KIR3DL1*00101, *002, *01502, *00501, *007, *004 and 3DS1*01301 alleles was assigned on the basis experimental data by Yawata et al. 51 For the remainders, the function was predicted on the basis of their highest sequence homologies with either strongly inhibiting 3DL1*015 allele (3DL1*008, *009 and *020) or weakly inhibiting allele 3DL1*005 (3DL1*019) per Norman et al. study.
52 KIR3DL1*003, *006, *01501, *016, *017 and *018, and 3DS1*010, *011, *012 and *014 alleles were not encountered in this study. KIR3DL1/S1-blank indicates individuals carrying a single 3DL1/3DS1 allele, and these individuals may carry two identical alleles of 3DL1/3DS1. 2DL2 þ C1 and 2DL3 þ C1 combinations, and found both increased in patients.
Sequence polymorphisms of 3DL1 and Bw4 affect their expression, binding and inhibitory function. 23 I80 that have been implicated as having the strongest inhibition 23, 51 and peptide-dependent KIR3DL1 þ HLA-A23/24/25/32 interactions 26 were found to be significantly decreased in patients compared to HLA-A*29 NC (Table 2) . Among the three predicted aKIR þ HLA combinations, KIR3DS1 þ Bw4 and KIR2DS2 þ HLA-C1 distributed equally in all three groups, while KIR2DS1 þ HLA-C2 was underrepresented in patients (Table 2 ). Nevertheless, patients displayed an increased frequency of KIR3DS1 þ NC (6%, P ¼ 2 Â 10 À10 , OR ¼ 13.3, 95% CI ¼ 5.39-33). In contrast, the presence of 3DL2 þ A3/11 with 3DL1 þ Bw4 and 2DL2/3 þ C1 (with or without 2DL1 þ C2) was less frequent in patients (9.1%) compared to HLA-A*29 PC (24.2%, P ¼ 0.0041, OR ¼ 0.31, 95% CI ¼ 0.14-0.7). In general, genotypes positive for 3DL2 þ A3/11 or lacking either 3DL1 þ Bw4 or 2DL2/3 þ C1, or both, 
Discussion
Strong association of HLA-A*29, 2 lymphocytic infiltration in the choroid 17 as well as the beneficial effects of immunosuppressive agents such as cyclosporine 54 in BCR clearly demonstrate the central role for an HLA-A29-restricted CTL response. The molecular or antigenic mimicry between the 'external' and 'self' peptide ligands of HLA-A29 may result in some activated CTLs having a response against self, which in turn may lead to autoimmunity. Supporting this model was the elution of retinal autoantigens from HLA-A29 molecules. 55 Predominance of KIR2DS2, 2DS3 and 2DS4, the genes implicated in autoimmune diseases [56] [57] [58] in BCR patients compared to HLA-A*29-matched controls, suggests that these aKIR receptors may enhance the T-cell autoreactivity. Although the direct role of NK cells in BCR pathogenesis is not clear, the genetic data presented herein indicate that KIR-HLA combinations likely influence both CTL and NK cell responses toward tolerance in controls and autoimmunity in BCR patients ( Figure 5 ).
In addition to providing self-tolerance, the interaction of iKIRs with self-HLA class I molecules confers NK cell functional competence, a process called 'licensing', 59 'arming' 60 or 'education'. 61 Expression of progressively higher numbers of iKIRs for self-HLA-B and HLA-Cw molecules has been correlated with an increased effector capacity. 62 Accordingly, most patients and controls studied here can generate highly competent NK cells as they express iKIRs for both HLA-B and HLA-Cw molecules. Relatively weaker inhibitory signals triggered by the predominant interactions of KIR2DL2/3 þ HLA-C1 and KIR3DL1 þ HLA-Bw4 T80 in patients may be sufficient to establish NK cell tolerance to self in the resting state, 27 but may be easily overcome by activating signals triggered in response to stress such as infection, leading to disease. The preponderance of autoimmunity- iKIR+HLA only iKIR+HLA+aKIR *** associated activating receptors KIR2DS2, 2DS3 and 2DS4 [56] [57] [58] in patients suggests that the interaction between these aKIRs and determinants expressed on the surface of stressed intraocular tissue trigger signals that may overcome the weaker inhibition, favoring localized NK cell hyperresponsiveness against self. Of note, individuals carrying the compound genotype (KIR2DL2/3 þ HLA-C1, KIR3DL1 þ HLA-Bw4 T80 and KIR2DS2/S3/S4) are extremely rare in black and Asian populations, 47 which is consistent with the epidemiology of BCR. 2 Alternatively, neighboring loci linked to 2DS2, 2DS3 and 2DS4 genes may also be involved in BCR pathogenesis.
HLA-A29 and its genetically linked HLA-B*4403 molecule carry a leucine residue at position 156 in the a2 helix and share high similarity in peptide-binding cleft (E pocket), which was implicated in loading unique peptides. 63 Since the HLA-B44 is the primary allotype contributing Bw4 ligand in HLA-A*29-positive subjects, the altered antigen-binding cleft may avoid its binding to inhibitory receptor KIR3DL1 as demonstrated with HLA-B*2705 molecules, 64 which in turn may further reduce inhibition and contribute to the increased NK and CTL activation.
Strong inhibitory combinations KIR3DL1 þ HLA-Bw4
I80
and KIR2DL1 þ HLA-C2 in HLA-A*29-negative controls may render protection against BCR. Predominance of KIR2DS1 þ HLA-C2 and KIR3DS1 þ HLA-Bw4 I80 combinations in controls raises the possibility that these weak interactions may be established only upon infection 4, 6, 65 and trigger NK response at the initial stage of infection, which perhaps avoids subsequent immune responses that may trigger inflammation and autoimmunity.
In conclusion, this study shows a strong association between certain allelic combination of 7 KIR and 3 HLA loci and risk of developing BCR. These data are consistent with loss of tolerance in BCR, perhaps in the context of infection, being in part mediated by cytotoxic lymphocytes expressing KIRs. A better understanding of the pathophysiology of disease provides the basis for designing strategies for screening and suggests that novel therapeutic approaches may be possible. 
Materials and methods
Study subjects and samples Genomic DNA samples from 110 unrelated patients with BCR and 197 unrelated healthy volunteer from a Caucasian population of France were included in this study. The patients were recruited at Hô pital Cochin, Paris, France. All patients met criteria for diagnosis of BCR that had been defined previously by an international group of investigators. 66 Briefly, the criteria include bilateral involvement; no more than mild (1 þ ) anterior uveitis or moderate (2 þ ) or less vitreous inflammatory reaction; and at least three hypopigmented choroidal lesions inferior or nasal to the optic disk. Although the presence of the HLA-A*29 allele was not required for the diagnosis of BCR, all patients included in this study had the HLA-A*29 allele.
The control DNA samples were collected at the CHU de Reims Champagne Ardenne, Reims, France. Controls were two groups: one group included samples collected randomly and another group included samples collected on the basis of HLA-A*29 positivity (n ¼ 95). We excluded the A*29-positive individuals (B5%) from the randomly collected control group, so that 102 individuals negative for HLA-A*29 were available in this group. The study adhered to the tenets of the Declaration of Helsinki for research involving human subjects. Fully informed consent was obtained from all subjects included in this study. The regional Comité Consultatif pour la Protection des Personnes se Prêtant à la Recherche Biomédicale and the UCLA Human Subject Protection Committee approved this study. The DNA samples were isolated from peripheral blood samples using a standard salting out method or QIAamp Blood Kit (Qiagen, Chatsworth, CA, USA). Quality and quantity of DNA was determined by UV spectrophotometry and the concentration was adjusted to 100 ng/ml. KIR and HLA genotyping DNA samples were typed for the presence and absence of 16 KIR genes using a gene-specific PCR typing system as described recently. 47 Using similar typing systems, the unexpressed alleles 2DS4*003/004/006, 2DS3*003N, 3DS1*049N, 3DL1*004 and 2DL2*004 were distinguished from their expressed counterparts, 47, 67 and only the expressed functional alleles were included for receptorligand analysis. HLA-A, -B and -C typing was performed by either sequence-specific primer-directed PCR amplification (PCR-SSP) or sequence-specific oligonucleotide hybridization methods using the commercial kits per manufacturer's instructions (One Lambda, Canoga Park, CA, USA). The KIR-binding HLA class I epitopes were predicted from the HLA typing results. If the HLA typing results were ambiguous, we SSP typed the KIR-binding HLA motifs as described earlier. 47 The presence of the following four iKIR þ HLA pairs was analyzed in each individual: 2DL1 þ HLA-C2, 2DL2/3 þ HLA-C1, 3DL1 þ HLA-Bw4 and 3DL2 þ HLA-A3/11. KIR3DL3 and 2DL5 were excluded from the study because their expression, ligand and function are not known. 18 Allele-level typing of KIR3DL1/S1 gene The function of different KIR3DL1 alleles was assigned on the basis functional studies and sequence homologies. 51, 52 Direct sequencing method was developed to characterize the allelic variants of KIR3DL1/S1. The strategy coupled gene-specific PCR amplification and direct sequencing of the amplified products after enzymatic purification, an approach we have successfully used for sequencing the KIR2DS3 and KIR3DS1 genes. 67 The 3DL1/S1-specific amplicon of B4.3 kb consists exons 3-5, which encodes the ligand-binding extracellular Iglike domains D0, D1 and D2. The oligonucleotide primers used in this direct DNA sequencing analysis are listed in Supplementary Table 2 .
Expand Long Template (LT) PCR System consisting Tgo DNA polymerase, a thermostable DNA polymerase with proofreading activity (Roche Applied Science, Indianapolis, IN, USA) was used to avoid miss-incorporation during the amplification of 3DL1/S1 gene. The PCR reaction (20 ml volume) consisted a final concentration of 1 Â LT buffer II, 500 mM of each deoxyribonucleotide triphosphates (dNTPs), 0.3 mM of each forward and reverse primers, 1.5 U of LT Tgo DNA polymerase and 100 ng genomic DNA. The thermal cycling conditions used for these PCR amplifications were 95 1C The PCR amplicons were purified from unincorporated primers and dNTPs by digesting with ExoSAP-IT exonuclease-I (USB Corporation, Cleveland, OH, USA) according to the manufacturer's protocol, and were used as template in the sequencing reactions. Exons 3, 4 and 5 were sequenced in both directions using the BigDye terminator V1.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA). The heterozygous DNA sequence analysis was performed using Assign SBT v3.5.1 software (Conexio Genomics, Applecross, Australia). The program combined both forward and reverse sequences, and generates a contiguous sequence from multiple exons. The Assign software compares the test sequence with a library of known KIR3DL1/S1 sequences and assigns the alleles.
The alleles identical in the region that we sequenced but differ in exon 2 and 9 were resolved by additional PCR-SSP typing. The typing system distinguished the following alleles and allele groups: 3DL1*007, 3DL1*016 and 3DS1*013, 3DL1*001/004/005/009 and 3DS1*010/011/ 012. The primers used for these typing are listed in the Supplementary Table 2. The PCR reagents used for these assays are same as those used recently for KIR genotyping. 47 The thermal cycling conditions used for this amplifications were 95 1C Data analysis and statistical methods Statistical analysis was performed using Stata 9 software. Differences between controls and patients in the distribution of KIR genes and their profiles were tested by two-tailed Fisher's exact probabilities (P), and Po0.05 was considered to be statistically significant. ORs with 95% CI were calculated for the comparisons showing significant difference between patient and control groups. Given the rarity of BCR disease the OR was interpreted as an approximation for relative risk.
